Screening for Alzheimer’s disease
02 May, 2013 by Susan WilliamsonThe development of a blood test for the early detection of Alzheimer’s disease takes a step forward.
Schubert steps onto Garvan board
01 May, 2013Dr John Schubert has been elected Chairman of the Board at the Garvan.
Australian-made malaria vaccine to enter human trials
30 April, 2013Australian researchers have developed the first malaria vaccine that can be tailored to combat the many variants of malaria that exist around the world. Human trials of the vaccine will begin next year.
Patrys cleared to escalate dose in myeloma trial
24 April, 2013 by Dylan Bushell-EmblingThe safety board monitoring Patrys’s (ASX:PAB) phase I/IIa trial of PAT-SM6 in multiple myeloma has cleared the company to move up to a higher dose.
Reigniting cell death
22 April, 2013Australian researchers have taken an important step towards designing a potential new anticancer agent.
Patrys cancer antibody binds to two targets
22 April, 2013 by Dylan Bushell-EmblingLab studies into Patrys’s (ASX:PAB) cancer treatment candidate PAT-SM6 show that the antibody can bind to two separate targets.
AbbVie’s rheumatology tool proves popular
18 April, 2013A new web-based educational tool is engaging rheumatologists.
Professional development in therapeutics
13 April, 2013The ARCS Congress is coming up in Sydney at the beginning of June.
Taking breast cancer research into the clinic
12 April, 2013A team of Melbourne researchers has received funding to take their work on a new class of anticancer drugs out of the lab and into the clinic.
Sirtex completes recruitment for SIRFLOX study
12 April, 2013 by Dylan Bushell-EmblingSirtex Medical (ASX:SRX) has signed on the final patient for SIRFLOX, a trial of its SIR-Spheres liver cancer treatments that has been recruiting since 2006.
Patrys doses second group in myeloma trial
11 April, 2013 by Dylan Bushell-EmblingPatrys (ASX:PAB) has completed initial treatment for half of the 12 multiple myeloma patients to be involved in a clinical trial of anticancer antibody PAT-SM6.
Viralytics’ Cavatak well-tolerated intravenously
10 April, 2013 by Dylan Bushell-EmblingA phase I trial of intravenous delivery of Viralytics’ (ASX:VLA) Cavatak shows that the viral cancer treatment candidate was well tolerated.
Record funding for cancer research in the west
08 April, 2013The Cancer Council of Western Australia recently allocated $2.8 million in annual funding for research in Western Australia.
Applications open for cancer research funding
03 April, 2013The 2013 round of funding from the Australian Cancer Research Foundation is now open.
Philanthropy, advocacy and vision
03 April, 2013 by Susan WilliamsonResearch Australia has formed a collaborative international alliance with three advocacy groups.
